Your Insulin of the Future Could Be " Made in China " if Big PBMs Have a Say in the Matter

Back on June 16, 2022, I published an article on LinkedIn entitled "How the Civica Insulin Announcement May Be Disruptive to the PBM Kickback Scheme" (see the article athttps://www.linkedin.com/pulse/how-civica-insulin-announcement-may-disruptive-pbm-scheme-strumello/ if you wish to read it) which predicted that a growing number of insulin biosimilars whose active pharmaceutical ingredients (API ' s) are cultured in offshore laboratories are forecast to hit the U.S. market in the next few years. According to the FDA and the individual companies whom I also follow on LinkedIn, the U.S. Food and Drug Administration (FDA) typically reviews their various insulin biosimilars Biologics License Applications (BLA ' s) about 11 months from the date the BLA ' s are filed, which means we are likely to start seeing the first of them hitting the market sometime in early 2024. However, the thesis of my article was that of the five companies (Biocon, Sandoz, Lannett, Amphastar and Civica) now anticipating FDA decisions on insulin biosimilars in the next year or two, only ONE of them was likely to have a truly " disruptive " impact patients ' insulin prices. Because of the very broken U.S. insulin market whereby PBMs are behind-the-scenes, manipulating prices to their own financial benefit while patients and employers alike pay ever-more and insulin manufacturers realized net prices have continued to decline, it really took the presence of a nonprofit drug company to fundamentally shake...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Congress insulin insulin prices lawmakers PBM Pharmacy Benefit Managers Source Type: blogs